Mucormycosis Market Research Report- Forecast till 2027

Mucormycosis Market research report: by diagnosis (Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia, Mucor), Diagnosis (CT, MRI, tissue biopsy), Treatment (surgery, antifungal), End user - Forecast till 2027

ID: MRFR/Pharma/3994-HCR | February 2021 | Region: Global | 120 pages

Mucormycosis Market Scenario:


Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. There are approximately 1.5 million different species of fungi on the earth, however, only around 300 are responsible for causing diseases and infections in humans. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.  


These infections need to be treated with prescribed antifungal medication, usually amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally. Often, mucormycosis requires surgery to remove the infected tissue.


The prognosis of mucormycosis is usually poor. It depends on various factors such as the overall health of the patient and ability to respond to treatments, the speed of diagnosis, and treatment provided. For instance, the mortality rate with rhinocerebral and GI mucormycosis is about 85% while the mortality rate for patients with other types of mucormycosis is about 50%. Patients who survive this infection often end up having disabilities such as blindness, limb loss, organ dysfunctions among others.


The market growth is mainly driven by increasing prevalence of fungal infections, availability of wide range of products, and rising incident of immunological diseases. Moreover, increasing awareness about fungal infection and increasing government support for research & development have fuelled the market growth. However, side effects of the treatment and presence of misbranded and spurious drugs may slow the growth of the market. There are a number of medicines available in the market for the treatment of fungal infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions, and pessaries.


Rising incidence of immunological diseases and availability of a wide range of products has driven the growth of the  mucormycosis market. Furthermore, rising geriatric population, increasing government support, and increasing healthcare expenditure have fueled the growth of the market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of the market.


The mucormycosis market is expected to grow at a CAGR of approximately 7.3% during the forecast period, 2017-2023.


Intended Audience:



  • Mucormycosis Drug Suppliers

  • Mucormycosis Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation:


The mucormycosis market is segmented on the basis of species, diagnosis, treatment, and end-users.


On the basis of the species, the mucormycosis market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others


On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.


On the basis of the treatment, the mucormycosis market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs is further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.


On the basis of the end-user, the mucormycosis market is segmented into hospitals & clinics, medical institutes, research organization, and others.


Regional Analysis:                     


The mucormycosis market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas dominate the mucormycosis market owing to a well-developed healthcare sector and huge patient population for mucormycosis. Many antifungal drugs have lost their patients during the last few years such as Terbinafine products like Lamisil lost their patient in 2017. As there is limited oral preparation in the market, development and licensing of new drugs in the market is the huge opportunity for the development of the market during the forecasted period.


Europe is the second largest market for the global mucormycosis owing to the advancements in the technology of the surgical devices along with the rising occurrence of fungal infections among the patients. The European government introduced incentives to help simplify the improvement of anti-infective drugs and dropping the risk and cost of manufacturers. Some other factors driving the market include the growing percentage of diabetes mellitus population mainly in the developed countries of Europe. The average diabetes prevalence rate in Europe is 8.6% of the adult population.


Asia Pacific is the fastest growing region for antifungal treatment due to increasing prevalence of HIV, and huge untapped growth opportunities for the development of the market. Every year, approximately 7.1% of the Korean population receives treatment for fungal diseases. Therefore, further research is needed to understand and monitor the prevalence of mycoses to establish management policies to reduce the burden of fungal diseases.


While the Middle East & Africa had the lowest share in antifungal treatment market, in 2016.


Key Players:


Some of key the players in the mucormycosis market are Abbott Laboratories (U.S.), Biocon Limited (India),  Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland),   Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   7.3% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Species, Diagnosis, Treatment, and End-users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories (U.S.), Biocon Limited (India), Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland), Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.), Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Increasing prevalence of fungal infections
  • Availability of wide range of products
  • Rising incident of immunological diseases


  • TABLE OF CONTENT


    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Treatment Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Mucormycosis market, by Species

    6.1 Introduction

    6.2 Rhizopus

    6.2.1 Market Estimates & Forecast, 2020 – 2027

    6.3 Rhizomucor

    6.3.1 Market Estimates & Forecast, 2020 – 2027

    6.4 Cunninghamella

    6.4.1 Market Estimates & Forecast, 2020 – 2027

    6.5 Apophysomyces

    6.5.1 Market Estimates & Forecast, 2020 – 2027

    6.6 Saksenaea

    6.6.1 Market Estimates & Forecast, 2020 – 2027

    6.7 Lichtheimia (Absidia)

    6.7.1 Market Estimates & Forecast, 2020 – 2027

    6.8 Mucor

    6.8.1 Market Estimates & Forecast, 2020 – 2027

    6.9 Others

    Chapter 7. Global Mucormycosis market, by Diagnosis

    7.1 Introduction

    7.2 Computed Tomography (CT)

    7.2.1 Market Estimates & Forecast, 2020 – 2027

    7.3 Magnetic resonance imaging (MRI)

    7.3.1 Market Estimates & Forecast, 2020 – 2027

    7.4 Tissue Biopsy

    7.4.1 Market Estimates & Forecast, 2020 – 2027

    7.5 Others

    Chapter 8. Global Mucormycosis market, by Treatment

    8.1 Introduction

    8.2 Surgery

    8.2.1 Market Estimates & Forecast, 2020 – 2027

    8.3 Antifungal drugs

    8.3.1 Market Estimates & Forecast, 2020 – 2027

    8.3.2 Posaconazole,

    8.3.2.1 Market Estimates & Forecast, 2020 – 2027

    8.3.3 Isavuconazole

    8.3.3.1 Market Estimates & Forecast, 2020 – 2027

    8.3.4 Voriconazole

    8.3.4.1 Market Estimates & Forecast, 2020 – 2027

    8.3.5 Fluconazole,

    8.3.5.1 Market Estimates & Forecast, 2020 – 2027

    8.3.6 Flucytosine

    8.3.6.1 Market Estimates & Forecast, 2020 – 2027

    8.3.7 Others

    8.4 Amphotericin B therapy

    8.4.1 Market Estimates & Forecast, 2020 – 2027

    8.5 Others

    Chapter 9. Global Mucormycosis market, by End User

    9.1 Introduction

    9.2 Hospitals & Clinics

    9.2.1 Market Estimates & Forecast, 2020 – 2027

    9.3 Medical Institutes

    9.3.1 Market Estimates & Forecast, 2020 – 2027

    9.4 Research Organization

    9.4.1 Market Estimates & Forecast, 2020 – 2027

    9.5 Others

    9.5.1 Market Estimates & Forecast, 2020 – 2027

    Chapter. 10 Global Mucormycosis market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 U.S.

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 U.K

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Rest of the Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 Abbott Laboratories

    12.1.1 Company Overview

    12.1.2 Diagnosis Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Biocon Limited

    12.2.1 Company Overview

    12.2.2 Diagnosis Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Cadila Pharmaceuticals Limited

    12.3.1 Company Overview

    12.3.2 Diagnosis Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Novartis AG

    12.4.1 Company Overview

    12.4.2 Diagnosis/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Merck & Co., Inc.

    12.5.1 Company Overview

    12.5.2 Diagnosis Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 F. Hoffman La Roche

    12.6.1 Company Overview

    12.6.2 Diagnosis Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 Merck Sharp and Dohme

    12.7.1 Overview

    12.7.2 Diagnosis Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Bristol Myers Squibb

    12.8.1 Company Overview

    12.8.2 Diagnosis/Business Segment Overview

    12.8.3 Financial Overview

    12.8.4 Key Development

    12.8.5 SWOT Analysis

    12.9 Pfizer Inc.

    12.9.1 Company Overview

    12.9.2 Diagnosis Overview

    12.9.3 Financial overview

    12.9.4 Key Developments

    12.10 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Pharmaceutical industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Mucormycosis Industry Synopsis, 2020 – 2027

    Table 2 Mucormycosis market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Mucormycosis market by Region, 2020 – 2027, (USD Million)

    Table 4 Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 5 Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 6 Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 7 Mucormycosis market by End Users, 2020 – 2027, (USD Million)

    Table 8 North America Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 9 North America Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 10 North America Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 11 North America Mucormycosis market by End User, 2020 – 2027, (USD Million)

    Table 12 US Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 13 US Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 14 US Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 15 US Mucormycosis market by End User, 2020 – 2027, (USD Million)

    Table 16 Canada Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 17 Canada Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 18 Canada Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 19 Canada Mucormycosis market by End User, 2020 – 2027, (USD Million)

    Table 20 South America Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 21 South America Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 22 South America Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 23 South America Mucormycosis market by End User, 2020 – 2027, (USD Million)

    Table 24 Europe Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 25 Europe Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 26 Europe Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 27 Europe Mucormycosis market by End User, 2020 – 2027, (USD Million)

    Table 28 Western Europe Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 29 Western Europe Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 30 Western Europe Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 31 Western Europe Mucormycosis market by End User, 2020 – 2027, (USD Million)

    Table 32 Eastern Europe Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 33 Eastern Europe Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 34 Eastern Europe Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 35 Eastern Europe Mucormycosis market by End User, 2020 – 2027, (USD Million)

    Table 36 Asia Pacific Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 37 Asia Pacific Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 38 Asia Pacific Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 39 Asia Pacific Mucormycosis market by End User, 2020 – 2027, (USD Million)

    Table 40 The Middle East & Africa Mucormycosis market by Species, 2020 – 2027, (USD Million)

    Table 41 The Middle East & Africa Mucormycosis market by Diagnosis, 2020 – 2027, (USD Million)

    Table 42 The Middle East & Africa Mucormycosis market by Treatment, 2020 – 2027, (USD Million)

    Table 43 The Middle East & Africa Mucormycosis market by End User, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Mucormycosis market

    Figure 3 Segmentation Market Dynamics for Mucormycosis market

    Figure 4 Global Mucormycosis market Share, by Species 2020

    Figure 6 Global Mucormycosis market Share, by Diagnosis 2020

    Figure 7 Global Mucormycosis market Share, by Treatment, 2020

    Figure 8 Global Mucormycosis market Share, by End Users, 2020

    Figure 9 Global Mucormycosis market Share, by Region, 2020

    Figure 10 North America Mucormycosis market Share, by Country, 2020

    Figure 11 Europe Mucormycosis market Share, by Country, 2020

    Figure 12 Asia Pacific Mucormycosis market Share, by Country, 2020

    Figure 13 The Middle East & Africa Mucormycosis market Share, by Country, 2020

    Figure 14 Global Mucormycosis market: Company Share Analysis, 2020 (%)

    Figure 15 Abbott Laboratories: Key Financials

    Figure 16 Abbott Laboratories: Segmental Revenue

    Figure 17 Abbott Laboratories: Geographical Revenue

    Figure 18 Biocon Limited: Key Financials

    Figure 19 Biocon Limited: Segmental Revenue

    Figure 20 Biocon Limited: Geographical Revenue

    Figure 21 Cadila Pharmaceuticals Limited : Key Financials

    Figure 22 Cadila Pharmaceuticals Limited : Segmental Revenue

    Figure 23 Cadila Pharmaceuticals Limited : Geographical Revenue

    Figure 24 Novartis AG: Key Financials

    Figure 25 Novartis AG: Segmental Revenue

    Figure 26 Novartis AG: Geographical Revenue

    Figure 27 Merck & Co., Inc.: Key Financials

    Figure 28 Merck & Co., Inc.: Segmental Revenue

    Figure 29 Merck & Co., Inc.: Geographical Revenue

    Figure 30 F. Hoffman La Roche: Key Financials

    Figure 31 F. Hoffman La Roche: Segmental Revenue

    Figure 32 F. Hoffman La Roche: Geographical Revenue

    Figure 33 Merck Sharp and Dohme: Key Financials

    Figure 34 Merck Sharp and Dohme: Segmental Revenue

    Figure 35 Merck Sharp and Dohme: Geographical Revenue

    Figure 36 Bristol Myers Squibb: Key Financials

    Figure 37 Bristol Myers Squibb: Segmental Revenue

    Figure 38 Bristol Myers Squibb: Geographical Revenue

    Figure 39 Pfizer Inc.: Key Financials

    Figure 40 Pfizer Inc.: Segmental Revenue

    Figure 41 Pfizer Inc.: Geographical Revenue